{"id":15460,"date":"2021-08-20T09:26:03","date_gmt":"2021-08-20T09:26:03","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\/"},"modified":"2026-02-11T09:48:54","modified_gmt":"2026-02-11T09:48:54","slug":"sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2","status":"publish","type":"post","link":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\/","title":{"rendered":"Sygnature et Epigeneron, la soci\u00e9t\u00e9 japonaise de biotechnologie, unissent leurs forces dans le cadre d’une collaboration."},"content":{"rendered":"

D\u00e9couvrir de nouvelles fronti\u00e8res : Sygnature et Epigeneron unissent leurs forces pour l’identification de cibles th\u00e9rapeutiques innovantes<\/h2>\n

Sygnature Discovery Ltd a entam\u00e9 une collaboration avec Epigeneron Inc.<\/a> , une soci\u00e9t\u00e9 japonaise de biotechnologie de premier plan qui utilise une technologie de pointe unique pour identifier des cibles m\u00e9dicamenteuses potentielles r\u00e9gulant l’expression des g\u00e8nes li\u00e9s \u00e0 la maladie.<\/p>\n

Les deux soci\u00e9t\u00e9s ont sign\u00e9 un accord de collaboration multi-projets visant \u00e0 d\u00e9velopper des compos\u00e9s de petites mol\u00e9cules ciblant de nouvelles cibles identifi\u00e9es par la technologie unique d’Epigeneron, combin\u00e9e \u00e0 l’expertise des scientifiques hautement qualifi\u00e9s de Sygnature.<\/p>\n

Epigeneron Inc., soci\u00e9t\u00e9 bas\u00e9e \u00e0 Tokyo et issue d’une universit\u00e9, est une entreprise de biotechnologie sp\u00e9cialis\u00e9e dans la d\u00e9couverte de m\u00e9dicaments \u00e9pig\u00e9n\u00e9tiques et le d\u00e9veloppement de traitements pour des maladies incurables telles que le cancer, la fibrose et les maladies du SNC (dont la d\u00e9pression et l’autisme).<\/p>\n

La technologie d’immunopr\u00e9cipitation de la chromatine (ChIP) sp\u00e9cifique de locus d’Epigeneron permet d’identifier les mol\u00e9cules physiquement associ\u00e9es aux r\u00e9gions g\u00e9nomiques d’int\u00e9r\u00eat. Les chercheurs peuvent ainsi concentrer leurs efforts sur l’analyse de ces mol\u00e9cules, ce qui augmente la probabilit\u00e9 que les prot\u00e9ines candidates constituant des cibles viables, sensiblement \u00e0 l’approche conventionnelle par \u00ab prot\u00e9ine candidate \u00bb. De plus, la ChIP sp\u00e9cifique de locus permet de d\u00e9tecter la redondance des prot\u00e9ines candidates et d’inhiber simultan\u00e9ment leurs fonctions. Les scientifiques peuvent donc commencer par les prot\u00e9ines candidates les plus pertinentes et mener une analyse approfondie. Par ailleurs, cette analyse permet de s\u00e9lectionner des prot\u00e9ines pr\u00e9sentant des profils d’expression ou des fonctions sp\u00e9cifiques dans les tissus pathologiques, ouvrant la voie \u00e0 la d\u00e9couverte de cibles \u00e9pig\u00e9n\u00e9tiques th\u00e9rapeutiques hautement pertinentes, avec des effets secondaires minimes dans les tissus sains. <\/p>\n

Le Dr Hiroki Wada<\/a> de Sygnature Discovery d\u00e9clare : \u00ab L’exp\u00e9rience \u00e9prouv\u00e9e de Sygnature dans le d\u00e9veloppement efficace de mol\u00e9cules candidates pour les essais cliniques, depuis la phase d’identification, combin\u00e9e \u00e0 la technologie de pointe d’Epigeneron, illustre un changement de paradigme par rapport aux approches traditionnelles de d\u00e9couverte de m\u00e9dicaments, au profit d’une m\u00e9thode plus flexible et innovante. Cette collaboration constitue un mod\u00e8le int\u00e9ressant pour les futures activit\u00e9s de recherche pharmaceutique entre le Royaume-Uni et le Japon. Le Japon est un march\u00e9 de plus en plus important pour Sygnature, et nous sommes impatients de d\u00e9velopper cette collaboration et de travailler en \u00e9troite collaboration avec l’\u00e9quipe d’Epigeneron. \u00bb <\/p>\n

Le PDG d’Epigeneron, Tetsuya Mishima, ajoute : \u00ab Nous sommes ravis d’entamer cette collaboration avec Sygnature Discovery et de concr\u00e9tiser la transformation de cibles de th\u00e9rapeutiques jusqu’alors inaccessibles en cibles accessibles. Cela permettra d’offrir de nouvelles options de traitement aux patients confront\u00e9s \u00e0 diverses difficult\u00e9s avec les th\u00e9rapies existantes. \u00bb <\/p>\n

Epigeneron a \u00e9t\u00e9 fond\u00e9e en avril 2015. Pour en savoir plus sur l’entreprise, cliquez ici.<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"category":[29],"tags":[],"class_list":["post-15460","post","type-post","status-publish","format-standard","hentry","category-non-categorise"],"acf":[],"yoast_head":"\nSygnature et Epigeneron, la soci\u00e9t\u00e9 japonaise de biotechnologie, unissent leurs forces dans le cadre d'une collaboration. - Sygnature<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sygnature et Epigeneron, la soci\u00e9t\u00e9 japonaise de biotechnologie, unissent leurs forces dans le cadre d'une collaboration. - Sygnature\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-20T09:26:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-11T09:48:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/02\/sygnature-hit-to-lead-team-collaboration-scaled.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"pnpd-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"pnpd-admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\\\/\"},\"author\":{\"name\":\"pnpd-admin\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/person\\\/9c173ed9f4225ab61ea895ac3a939448\"},\"headline\":\"Sygnature et Epigeneron, la soci\u00e9t\u00e9 japonaise de biotechnologie, unissent leurs forces dans le cadre d’une collaboration.\",\"datePublished\":\"2021-08-20T09:26:03+00:00\",\"dateModified\":\"2026-02-11T09:48:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\\\/\"},\"wordCount\":540,\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Non cat\u00e9goris\u00e9\"],\"inLanguage\":\"fr-CA\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\\\/\",\"name\":\"Sygnature et Epigeneron, la soci\u00e9t\u00e9 japonaise de biotechnologie, unissent leurs forces dans le cadre d'une collaboration. - Sygnature\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"datePublished\":\"2021-08-20T09:26:03+00:00\",\"dateModified\":\"2026-02-11T09:48:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/page-daccueil\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sygnature et Epigeneron, la soci\u00e9t\u00e9 japonaise de biotechnologie, unissent leurs forces dans le cadre d’une collaboration.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature Discovery\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature Discovery\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/person\\\/9c173ed9f4225ab61ea895ac3a939448\",\"name\":\"pnpd-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g\",\"caption\":\"pnpd-admin\"},\"sameAs\":[\"http:\\\/\\\/www.sygnaturediscovery.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sygnature et Epigeneron, la soci\u00e9t\u00e9 japonaise de biotechnologie, unissent leurs forces dans le cadre d'une collaboration. - Sygnature","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\/","og_locale":"fr_CA","og_type":"article","og_title":"Sygnature et Epigeneron, la soci\u00e9t\u00e9 japonaise de biotechnologie, unissent leurs forces dans le cadre d'une collaboration. - Sygnature","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\/","og_site_name":"Sygnature","article_published_time":"2021-08-20T09:26:03+00:00","article_modified_time":"2026-02-11T09:48:54+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/02\/sygnature-hit-to-lead-team-collaboration-scaled.webp","type":"image\/webp"}],"author":"pnpd-admin","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"pnpd-admin","Estimation du temps de lecture":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\/#article","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\/"},"author":{"name":"pnpd-admin","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/person\/9c173ed9f4225ab61ea895ac3a939448"},"headline":"Sygnature et Epigeneron, la soci\u00e9t\u00e9 japonaise de biotechnologie, unissent leurs forces dans le cadre d’une collaboration.","datePublished":"2021-08-20T09:26:03+00:00","dateModified":"2026-02-11T09:48:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\/"},"wordCount":540,"publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"articleSection":["Non cat\u00e9goris\u00e9"],"inLanguage":"fr-CA"},{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\/","name":"Sygnature et Epigeneron, la soci\u00e9t\u00e9 japonaise de biotechnologie, unissent leurs forces dans le cadre d'une collaboration. - Sygnature","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"datePublished":"2021-08-20T09:26:03+00:00","dateModified":"2026-02-11T09:48:54+00:00","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/sygnature-et-epigeneron-la-societe-japonaise-de-biotechnologie-unissent-leurs-forces-dans-le-cadre-dune-collaboration-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/page-daccueil\/"},{"@type":"ListItem","position":2,"name":"Sygnature et Epigeneron, la soci\u00e9t\u00e9 japonaise de biotechnologie, unissent leurs forces dans le cadre d’une collaboration."}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature Discovery","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature Discovery"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/person\/9c173ed9f4225ab61ea895ac3a939448","name":"pnpd-admin","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/secure.gravatar.com\/avatar\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/052476d339a267f4be89460f64dd24ba52137529feafa9cf45d6e8b2b62cda8b?s=96&d=mm&r=g","caption":"pnpd-admin"},"sameAs":["http:\/\/www.sygnaturediscovery.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/posts\/15460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/comments?post=15460"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/posts\/15460\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=15460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=15460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/tags?post=15460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}